Amgen Drives Into Immunotherapy With Early Blinatumomab BLA
This article was originally published in The Pink Sheet Daily
Bispecific leukemia drug goes to FDA ahead of Phase III data in what could be a signature moment for the agency’s breakthrough designation program – and the company’s cancer deal-making.
You may also be interested in...
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
Merck, Lilly, Gilead and Celgene are among the companies striking deals that involve bispecific antibodies. The novel dual-acting drugs have been in development since the 1980s with little success, yet big pharma believes they may finally be coming of age.
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).